DATADRIVENPHARMA Trademark

Trademark Overview

On Wednesday, March 19, 2025, a trademark application was filed for DATADRIVENPHARMA with the United States Patent and Trademark Office. The USPTO has given the DATADRIVENPHARMA trademark a serial number of 99975116. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, May 5, 2026. This trademark is owned by Data Driven Pharma LLC. The DATADRIVENPHARMA trademark is filed in the Education & Entertainment Services category with the following description:

Conducting of conferences in the field of pharmaceuticals and biotechnology
datadrivenpharma

General Information

Serial Number99975116
Word MarkDATADRIVENPHARMA
Filing DateWednesday, March 19, 2025
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, May 5, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesConducting of conferences in the field of pharmaceuticals and biotechnology

Classification Information

International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateWednesday, March 19, 2025
Primary Code041
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameData Driven Pharma LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressWalnut Creek, CA 94597
US

Trademark Events

Event DateEvent Description
Wednesday, March 19, 2025NEW APPLICATION ENTERED
Wednesday, March 19, 2025APPLICATION FILING RECEIPT MAILED
Thursday, July 10, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 19, 2025ASSIGNED TO EXAMINER
Wednesday, September 3, 2025NON-FINAL ACTION WRITTEN
Wednesday, September 3, 2025NON-FINAL ACTION E-MAILED
Wednesday, September 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 8, 2025TEAS PETITION TO REVIVE RECEIVED
Monday, December 8, 2025PETITION TO REVIVE-GRANTED
Monday, December 8, 2025NOTICE OF REVIVAL - E-MAILED
Monday, December 8, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 8, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 8, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 2, 2026ASSIGNED TO EXAMINER
Thursday, February 5, 2026NON-FINAL ACTION WRITTEN
Thursday, February 5, 2026NON-FINAL ACTION E-MAILED
Thursday, February 5, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 5, 2026TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, May 5, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 5, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 5, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 14, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 5, 2026DIVISIONAL REQUEST RECEIVED
Tuesday, May 19, 2026DIVISIONAL PROCESSING COMPLETE

Related Keywords

datadrivenpharma biotechnology pharmaceuticals field conferences conducting